Influence of immunotherapy with pegylated interferon-alpha on platelet monoamine oxidase activity in high-risk melanoma patients

被引：0
|
作者：
Fekkes, D [1 ]
van Gool, AR [1 ]
van Ojik, HH [1 ]
Bannink, M [1 ]
Mulder, PGH [1 ]
Kruit, WHJ [1 ]
Eggermont, AMM [1 ]
Stoter, G [1 ]
机构：
[1] Erasmus Univ, Med Ctr, Rotterdam, Netherlands
来源：
EUROPEAN NEUROPSYCHOPHARMACOLOGY | 2004年 / 14卷
关键词：
D O I：
10.1016/S0924-977X(04)80165-2
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
引用
收藏
页码：S206 / S207
页数：2
相关论文
共 50 条
  • [21] ADJUVANT IMMUNOTHERAPY - TREATMENT OF HIGH-RISK PATIENTS WITH MALIGNANT-MELANOMA
    THOMAS, JH
    MALONEY, BE
    JEWELL, WR
    JOURNAL OF THE KANSAS MEDICAL SOCIETY, 1978, 79 (03): : 107 - 110
  • [22] Induction of Autoimmunity by Pegylated Interferon-alpha-2b in Correlation to Survival Time in Medium and High Risk Melanoma Patients
    Loquai, C.
    Schlueter, B.
    Kloetgen, H. W.
    Luger, T. A.
    Grabbe, S.
    Nashan, D.
    AKTUELLE DERMATOLOGIE, 2008, 34 (05) : 170 - 174
  • [23] Overactivation of STAT3 by interferon-alpha may negatively influence disease outcome in melanoma patients
    Humpolikova, L. Adamkova
    Kovank, A.
    Dusek, L.
    Lauerova, L.
    Boudny, V.
    Kovarik, J.
    EJC SUPPLEMENTS, 2008, 6 (09): : 144 - 144
  • [24] Improving survival in patients with high-risk and metastatic melanoma - Immunotherapy leads the way
    Agarwala, SS
    AMERICAN JOURNAL OF CLINICAL DERMATOLOGY, 2003, 4 (05) : 333 - 346
  • [25] Does pegylated interferon α-2b confer additional benefit in the adjuvant treatment of high-risk melanoma?
    Kirkwood, John M.
    Tawbi, Hussein A.
    Tarhini, Ahmad A.
    Moschos, Stergios J.
    NATURE CLINICAL PRACTICE ONCOLOGY, 2009, 6 (02): : 70 - 71
  • [26] Does pegylated interferon α-2b confer additional benefit in the adjuvant treatment of high-risk melanoma?
    John M Kirkwood
    Hussein A Tawbi
    Ahmad A Tarhini
    Stergios J Moschos
    Nature Clinical Practice Oncology, 2009, 6 : 70 - 71
  • [27] Cost-effectiveness of interferon for high-risk (stage III) melanoma patients
    Guillem, V
    Alvarez-Mon, M
    Camacho, F
    Diaz-Perez, JL
    Diaz-Rubio, E
    Gonzalez-Larriba, JL
    Lopez-Lopez, JJ
    Moreno, JA
    Serrano, S
    Toribio, J
    EUROPEAN JOURNAL OF CANCER, 1999, 35 : S372 - S372
  • [28] Economic analysis of interferon for high-risk (stage III) melanoma patients.
    González-Larriba, JL
    Alvarez-Mon, M
    Camacho, F
    Casado, MA
    Díaz-Pérez, JL
    Díaz-Rubio, E
    Guillem, V
    López-López, JJ
    Moreno, JA
    Serrano, S
    Toribio, J
    EUROPEAN JOURNAL OF CANCER, 1999, 35 : S50 - S50
  • [29] Economic analyses of benefit from interferon-alpha 2B in high-risk melanoma: Trade-offs between completeness, simplicity and clarity
    Hillner, BE
    Kirkwood, JM
    EUROPEAN JOURNAL OF CANCER, 1997, 33 (09) : 1345 - 1346
  • [30] Adjuvant Therapy of High-Risk (Stages IIC-IV) Malignant Melanoma in the Post Interferon-Alpha Era: A Systematic Review and Meta-Analysis
    Christofyllakis, Konstantinos
    Pfoehler, Claudia
    Bewarder, Moritz
    Mueller, Cornelia S. L.
    Thurner, Lorenz
    Rixecker, Torben
    Vogt, Thomas
    Stilgenbauer, Stephan
    Yordanova, Krista
    Kaddu-Mulindwa, Dominic
    FRONTIERS IN ONCOLOGY, 2021, 10
12345